<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613638</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC/10-02 - PENEW</org_study_id>
    <secondary_id>B110827-40</secondary_id>
    <secondary_id>11/22-811</secondary_id>
    <secondary_id>2010-A01445-34</secondary_id>
    <nct_id>NCT01613638</nct_id>
  </id_info>
  <brief_title>Pregnancy Environment and Newborn Malformations</brief_title>
  <acronym>PENEW</acronym>
  <official_title>Congenital Malformations and Intrauterine Pollutants Exposure (Alcohol, Solvents and Pesticides) in Brittany. Population Based Case-control Study Short Title : Malformations and Environment Acronym : PENEW for &quot;Pregnancy Environment and Newborn Malformations&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Congenital malformations rate is about 3% in France. There are already 5 registries in&#xD;
      France, covering about 16% of French births: Paris Registry, (about 38 000 births /year),&#xD;
      Alsace Registry, (about 23 000 births/year), Rhône-Alpes Registry, (about 56 000&#xD;
      births/year), Auvergne Registry, (about 14 000 births/year), and la Réunion Registry. The aim&#xD;
      of malformation registries is to carry out epidemiologic surveillance of congenital&#xD;
      anomalies. The objectives are mainly to provide essential epidemiologic information on&#xD;
      congenital anomalies, to facilitate the early warning of teratogenic exposures, to act as an&#xD;
      information and resource centre regarding clusters, to provide data for research related to&#xD;
      the causes and prevention of congenital anomalies.&#xD;
&#xD;
      A previous study was carried out in Brittany in 2008-2009, by the perinatal network of Ille&#xD;
      et Vilaine, in collaboration with two research teams (Inserm U1085 and Inserm U 936), to&#xD;
      record all cases of 4 types of congenital anomalies: congenital heart disease, spina bifida,&#xD;
      diaphragmatic hernia and hypospadia. The results showed prevalence rates similar to those&#xD;
      observed by Eurocat for spina bifida and diaphragmatic hernia, but a higher prevalence&#xD;
      regarding congenital heart diseases and hypospadia. In this study the investigators could not&#xD;
      determine whether this was due to a real higher frequency or to a particular exhaustiveness&#xD;
      in the recording methodology.&#xD;
&#xD;
      There are hypothesis about the role of intrauterine exposure to pesticides, known as&#xD;
      endocrine disruptors, and the risk of congenital genital anomalies. Brittany is an intensive&#xD;
      agricultural area, and it is thus worth studying the impact of pesticides exposure on&#xD;
      congenital anomalies.&#xD;
&#xD;
      There are also hypothesis on the impact of occupational exposure to solvents on congenital&#xD;
      anomalies (Garlantezec 2009), and on the role of alcohol exposure (which concerns about 8%&#xD;
      pregnant women in France) on oro-facial clefts and congenital heart diseases.&#xD;
&#xD;
      The Registry of congenital anomalies in Brittany was set up in 2010. The main aim is to study&#xD;
      the impact of intra-uterine exposure to solvents, pesticides and alcohol on the risk of&#xD;
      congenital malformations diagnosed at births, by measuring the exposure both directly in&#xD;
      meconium, and indirectly by questionnaires.&#xD;
&#xD;
      Secondary objectives are to study other risk factors such as medicine intake, pregnancy&#xD;
      illness…&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Population based case-control study:&#xD;
&#xD;
      2 controls per case will be included, corresponding to the first 2 births without congenital&#xD;
      anomalies, with same sex and same birth place, following the case.&#xD;
&#xD;
      INVESTIGATION METHODOLOGY :&#xD;
&#xD;
      All maternity in Brittany were proposed to participate. In each maternity, the referent&#xD;
      practitioner informs the parents and includes the cases.&#xD;
&#xD;
      For each case and control, meconium samples and a mother's lock are collected by nurses or&#xD;
      midwives, medical data are collected from medical reports by the registry investigator, and a&#xD;
      self-questionnaire is filled by the mother.&#xD;
&#xD;
      Meconium samples are immediately stored in a freezer (-20°C), secondarily transported to a&#xD;
      biological storage centre at the university hospital and then dispatched to specialised&#xD;
      laboratories for toxicological analyses: INERIS (for solvents and pesticides) and Toxicology&#xD;
      Unit, University hospital Rennes (for Alcohol).&#xD;
&#xD;
      For dead fetuses (stillbirths or termination of pregnancy), meconium will be collected by the&#xD;
      pathologist in charge of the autopsy, after parents' consent.&#xD;
&#xD;
      Evaluation of exposure:&#xD;
&#xD;
        -  direct evaluation: by toxicological analyses in meconium samples: Alcohol, Solvents and&#xD;
           pesticides&#xD;
&#xD;
        -  indirect evaluation: by maternal self-questionnaire including data on occupational and&#xD;
           domestic exposures, hobbies, life habits…, precise address (for spatial location)&#xD;
&#xD;
      Particular cases: mild congenital heart defects, genital anomalies and hip dislocation&#xD;
      diagnosed later after birth (after the period oh meconium and before the age of one): these&#xD;
      cases will be spotted through the Registry, there won't be any biological sample for them,&#xD;
      but mothers will be contacted by main investigator and medical data and mother questionnaires&#xD;
      will be collected. There won't be any control included for those cases included after birth.&#xD;
&#xD;
      Associations between exposure risk factors (alcohol, solvents and pesticides) and the risk of&#xD;
      congenital malformations will be estimated by a multivariate analysis.&#xD;
&#xD;
        -  Exposure to solvents will be estimated by assay in meconium and by occupational&#xD;
           questionnaire&#xD;
&#xD;
        -  Exposure to alcohol will be estimated by assay of Ethylglucuronide et de Ethylsulfate in&#xD;
           meconium.&#xD;
&#xD;
        -  Exposure to pesticides will be estimated by assay in meconium, by questionnaire and by&#xD;
           spatial location.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2012</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>impact of intra-uterine exposure to solvents, pesticides and alcohol on the risk of congenital malformations diagnosed at births, by measuring the exposure both directly in meconium, and indirectly by questionnaires.</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>impact of intra-uterine exposure to solvents, pesticides and alcohol on the risk of congenital malformations diagnosed at births, by measuring the exposure both directly in meconium, and indirectly by questionnaires.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>other risk factors such as medicine intake, pregnancy illness…</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>other risk factors such as medicine intake, pregnancy illness…</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1657</enrollment>
  <condition>Congenital Malformation</condition>
  <arm_group>
    <arm_group_label>Congenital malformations</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All livebirths, fetal deaths with gestational age (GA) ≥22 weeks and terminations of pregnancy (at any gestational age) after prenatal diagnosis of malformation.&#xD;
born from mothers living in Brittany at delivery&#xD;
with a congenital anomaly according to Eurocat criteria, diagnosed or suspected (and then confirmed) at birth&#xD;
or with mild congenital heart defects, genital anomalies or hip dislocation diagnosed after birth (and before the age of one)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>2 controls per case will be included, corresponding to the first 2 births without congenital anomalies, with same sex and same birth place, following the case.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>meconium samples + maternal self-questionnaire</intervention_name>
    <description>meconium samples + maternal self-questionnaire</description>
    <arm_group_label>Congenital malformations</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All live births, fetal deaths with gestational age (GA) ≥22 weeks and terminations of&#xD;
        pregnancy for medical reasons (IMG) from 20 weeks of amenorrhea (SA) included.&#xD;
&#xD;
          -  born from mothers living in Brittany at delivery&#xD;
&#xD;
          -  with a congenital anomaly according to Eurocat criteria, diagnosed or suspected (and&#xD;
             then confirmed) at birth&#xD;
&#xD;
          -  or with mild congenital heart defects, genital anomalies or hip dislocation diagnosed&#xD;
             after birth (and before the age of one) Suspicion of chromosomal abnormality or&#xD;
             genetic syndrome on purely clinical criteria but not yet authenticated by genetic&#xD;
             analyzes. If the chromosomal or genetic abnormalities are secondarily authenticated,&#xD;
             these cases will be excluded a posteriori.&#xD;
&#xD;
        Non inclusion criteria :&#xD;
&#xD;
          -  Spontaneous abortion before 22 weeks gestational age.&#xD;
&#xD;
          -  IMG before the 20 week term amenorrhea&#xD;
&#xD;
          -  Chromosomal abnormalities or syndromes genetic authenticated by karyotype or analysis&#xD;
             in molecular biology, in antenatal&#xD;
&#xD;
          -  Mother with legal protection (guardianship)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prenatally suspected malformations, which are not confirmed by postnatal screening or&#xD;
             clinical evolution&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence Rouget, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Lefevre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fougères Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joëlle Gueguen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Grégoire Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle Blanchot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique La Sagesse - Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Vernis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Malo hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique Chaumet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vitré Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Abi-Fadel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Redon Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Rebour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lannion Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Turban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dinan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire Combescure, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Brieuc Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Magagi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Polyclinique du Littoral - Saint-Brieuc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Collet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Brest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Somerville, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Polyclinique de Keraudren - Brest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain Hassoun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur - Brest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Bellot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quimper Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Tillaut, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lorient Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hubert Journel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vannes Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire Duhaut, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Océane - Vannes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Vallée, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontivy Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Agnès Guillou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ploermël Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Polyclinique de Keraudren</name>
      <address>
        <city>Brest</city>
        <state>Brittany</state>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brest University Hospital</name>
      <address>
        <city>Brest</city>
        <state>Brittany</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lannion Hospital</name>
      <address>
        <city>Lannion</city>
        <state>Brittany</state>
        <zip>22303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lorient Hospital</name>
      <address>
        <city>Lorient</city>
        <state>Brittany</state>
        <zip>56322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ploermel Hospital</name>
      <address>
        <city>Ploermel</city>
        <state>Brittany</state>
        <zip>56804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quimper Hospital</name>
      <address>
        <city>Quimper</city>
        <state>Brittany</state>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <state>Brittany</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Brieuc Hospital</name>
      <address>
        <city>Saint-Brieuc</city>
        <state>Brittany</state>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Grégoire Hospital</name>
      <address>
        <city>Saint-Grégoire</city>
        <state>Brittany</state>
        <zip>35760</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Océane</name>
      <address>
        <city>Vannes</city>
        <state>Brittany</state>
        <zip>56000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vannes Hospital</name>
      <address>
        <city>Vannes</city>
        <state>Brittany</state>
        <zip>56000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 24, 2012</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>congenital malformation</keyword>
  <keyword>pollutants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

